Bonvita

Still going strong

A choice of one tablet, once monthly1 or a quarterly IV injection2

Because compliance
is important

For treatment of osteoporosis in post-menopausal women at increased risk of fracture1,2

BONVIVA ONCE MONTHLY TABLET1

PREFERENCE

66% of women preferred a once-monthly ibandronate regimen to a once-weekly alendronate regimen (p<0.0001)3

COMPLIANCE

The primary reason that patients chose ibandronate in the present study were that the once-monthly regimen fits better into their lifestyle and was easier to follow over a long period of time3

Bone Mineral Density (BMD) increases after 5 years’ continuous monthly treatment with Bonviva4

LONG-TERM BENEFITS
  • Bonviva 150mg monthly sustains BMD increases long-term4
  • At 5 years improvements in total hip, femoral neck and trochanter BMD (achieved after 2 years of initial treatment with Bonviva 150mg once monthly) were maintained4
  • Bonviva once-monthly showed a significantly lower relative risk of vertebral fracture than in patients on weekly bisphosphonates5
BONVIVA ONCE-MONTHLY HAS GOOD TOLERABILITY1
  • Common adverse reactions (≥ 1/100 to < 1/10):1 Headache, Oesophagitis, Gastritis, Gastro oesophageal reflux disease, Dyspepsia, Diarrhoea, Abdominal pain, Nausea, Rash, Arthralgia, Myalgia, Musculoskeletal pain, Muscle cramp, Musculoskeletal stiffness, Influenza like illness1
  • Bonviva 150mg once-monthly has a tolerability profile comparable to weekly alendronate6

BONVIVA QUARTERLY IV INJECTION2

PREFERENCE

Some women may prefer their osteoporosis therapy to be administered quarterly IV rather than orally once-monthly7

Bonviva quarterly IV provides an alternative if patients fail to respond adequately to oral bisphosphonate treatment8

COMPLIANCE

Bonviva 3mg injection is physician administered once every 3 months2

Mean relative BMD increases from baseline at 2 years with Bonviva quarterly intravenous (IV) injection2

LONG-TERM BENEFITS
  • After 5 years of continuous Bonviva quarterly IV injection, lumbar spine BMD increased by 8.1% vs. baseline9,10
BONVIVA 3MG QUARTERLY IV INJECTION HAS DEMONSTRATED GOOD TOLERABILITY2,10
  • Common adverse reactions (≥ 1/100 to < 1/10):1 Headache, Gastritis, Dyspepsia, Diarrhoea, Abdominal pain, Nausea, Constipation, Rash, Arthralgia, Myalgia, Musculoskeletal pain, Back pain, Influenza like illness, Fatigue2
  • No new or unexpected safety signals were identified over 5 years with Bonviva quarterly IV injections10

References

  1. Bonviva 150 mg film-coated tablets Summary of Product Characteristics.
  2. Bonviva 3 mg solution for injection Summary of Product Characteristics.
  3. Emkey R, Kolten K, Beusterein K, et al. Curr Med Res Opin. 2005 Dec;21(12):1895-903.
  4. Miller PD, Recker RR, Reginster J-Y, et al. Osteoporos Int. 2012;23:1747–1756.
  5. Harris ST, et al. Bone. 2009 May;44(5):758-65.
  1. Miller PD, Epstein S, Sedarati F, et al. Curr Med Res & Opin. 2008;24(1):207–213.
  2. Lewiecki EM, Babbitt AM, Piziak VK, et al. Clin Ther. 2008;30(4):605–621.
  3. Bae SJ, Kim B-J, Lim KH, et al. J Bone Miner Metab. 2012;30:588–595.
  4. Munno OD, Sedie AD. Clin Cases in Min and Bone Met. 2010;7(1):23–26.
  5. Bianchi G, Czerminski E, Kenwright A et al. Osteoporosis Int. 2012;23:1769–1778.
Abbreviated prescribing
information
Patient information
leaflet - Tablet
Patient information
leaflet - Injection
Summary of Product
Characteristics - Tablet
Summary of Product
Characteristics - Injection

Contact Us

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to ATNAHS Pharma UK Ltd on 00 44 (0) 1279 406759, or by email to atnahspv@diamondpharmaservices.com

I have read & accept the Privacy Policy